Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 22.51 -0.79% -0.18
SUPN closed down 0.79 percent on Tuesday, December 10, 2019, on approximately normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
See historical SUPN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
20 DMA Support Bullish 0.00%
Outside Day Range Expansion 0.00%
NR7 Range Contraction -0.79%
Crossed Above 20 DMA Bullish -1.40%
Fell Below 20 DMA Bearish 2.50%
Inside Day Range Contraction -1.75%
20 DMA Support Bullish -2.30%
Pocket Pivot Bullish Swing Setup -2.30%
Inside Day Range Contraction -2.30%
Older signals for SUPN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
Health Pharmaceutical Pharmaceutical Industry Drug Discovery Clinical Trial Design Of Experiments Epilepsy Clinical Research Attention Deficit Hyperactivity Disorder Depression Clinical Trial Product Central Nervous System Diseases Neurology Treatment Of Central Nervous System Diseases Treatment Of Depression Treatment Of Epilepsy

Is SUPN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 43.05
52 Week Low 19.35
Average Volume 670,561
200-Day Moving Average 30.76
50-Day Moving Average 24.60
20-Day Moving Average 22.32
10-Day Moving Average 22.71
Average True Range 0.96
ADX 23.85
+DI 15.60
-DI 27.27
Chandelier Exit (Long, 3 ATRs ) 20.72
Chandelier Exit (Short, 3 ATRs ) 23.37
Upper Bollinger Band 23.32
Lower Bollinger Band 21.32
Percent B (%b) 0.59
BandWidth 8.98
MACD Line -0.54
MACD Signal Line -0.74
MACD Histogram 0.1978
Fundamentals Value
Market Cap 1.14 Billion
Num Shares 50.7 Million
EPS 1.98
Price-to-Earnings (P/E) Ratio 11.37
Price-to-Sales 8.00
Price-to-Book 8.81
PEG Ratio 1.42
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.52
Resistance 3 (R3) 24.53 23.86 24.19
Resistance 2 (R2) 23.86 23.35 23.86 24.07
Resistance 1 (R1) 23.19 23.04 22.86 23.18 23.96
Pivot Point 22.52 22.52 22.36 22.52 22.52
Support 1 (S1) 21.85 22.01 21.52 21.84 21.06
Support 2 (S2) 21.18 21.70 21.18 20.95
Support 3 (S3) 20.51 21.18 20.84
Support 4 (S4) 20.50